State Street
JANX icon

State Street’s Janux Therapeutics JANX Stock Holding History

State Street’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$46.2M Buy
3,004,899
+540,882
+22% +$7.84M ﹤0.01% 1895
2026
Q1 		$34.2M Sell
2,464,017
-1,389,934
-36% -$19.1M ﹤0.01% 1943
2025
Q4 		$53.2M Buy
3,853,951
+1,962,486
+104% +$46.2M ﹤0.01% 1706
2025
Q3 		$46.2M Buy
1,891,465
+503,357
+36% +$12.3M ﹤0.01% 1763
2025
Q2 		$32.1M Buy
1,388,108
+16,611
+1% +$438K ﹤0.01% 1927
2025
Q1 		$37M Buy
1,371,497
+103,548
+8% +$3.9M ﹤0.01% 1806
2024
Q4 		$67.9M Sell
1,267,949
-93,229
-7% -$4.93M ﹤0.01% 1561
2024
Q3 		$61.8M Sell
1,361,178
-40,056
-3% -$1.74M ﹤0.01% 1597
2024
Q2 		$58.7M Buy
1,401,234
+1,001,767
+251% +$47M ﹤0.01% 1581
2024
Q1 		$15M Buy
399,467
+51,882
+15% +$1.13M ﹤0.01% 2338
2023
Q4 		$3.73M Buy
347,585
+16,014
+5% +$138K ﹤0.01% 3085
2023
Q3 		$3.34M Sell
331,571
-1,019
-0.3% -$11.8K ﹤0.01% 3108
2023
Q2 		$3.95M Buy
332,590
+33,961
+11% +$454K ﹤0.01% 3114
2023
Q1 		$3.61M Buy
298,629
+15,519
+5% +$258K ﹤0.01% 3113
2022
Q4 		$3.73M Buy
283,110
+18,903
+7% +$277K ﹤0.01% 3169
2022
Q3 		$3.58M Buy
264,207
+185
+0.1% +$2.47K ﹤0.01% 3220
2022
Q2 		$3.22M Buy
264,022
+22,024
+9% +$261K ﹤0.01% 3310
2022
Q1 		$3.47M Buy
241,998
+30,432
+14% +$498K ﹤0.01% 3345
2021
Q4 		$4.17M Buy
211,566
+36,922
+21% +$774K ﹤0.01% 3327
2021
Q3 		$3.78M Buy
+174,644
New +$5.02M ﹤0.01% 3378

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street's JANX Position: Q2 2026 in Review

State Street increased its Janux Therapeutics (JANX) stake by 22% in Q2 2026, buying an estimated $7.84M and bringing the position to 3,004,899 shares worth $46.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1895.

State Street first reported a position in JANX in Q3 2021 and has held it in 20 quarters since. The position peaked at $67.9M in Q4 2024. 198 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • State Street held 3,004,899 shares of Janux Therapeutics worth $46.2M as of Q2 2026.
  • State Street bought 540,882 Janux Therapeutics shares in Q2 2026, an estimated $7.84M.
  • Janux Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #1895 holding.
  • State Street first reported a position in Janux Therapeutics in Q3 2021 and has held it in 20 quarters since.
  • State Street's Janux Therapeutics position peaked at $67.9M in Q4 2024.
  • 198 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.